Ocular toxicity of fludarabine: a purine analog

被引：19

作者：

Ding, Xiaoyan ^{[1
,2
,3
]}

Herzlich, Alexandra A. ^{[1
,2
]}

Bishop, Rachel ^{[1
,2
]}

Tuo, Jingsheng ^{[1
,2
]}

Chan, Chi-Chao ^{[1
]}

机构：

[1] NEI Bethesda, NIH, 10 Ctr Dr,Bldg 10,Room 10N103, Bethesda, MD 20892 USA

[2] NEI, Natl Inst Hlth, Immunopathol Sect, Immunol Lab, Bethesda, MD USA

[3] Sun Yet Sen Univ, Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China

来源：

EXPERT REVIEW OF OPHTHALMOLOGY | 2008年 / 3卷 / 01期

关键词：

fludarabine; neurotoxicity; ocular toxicity; ophthalmic pathology; pharmacogenetics; purine analog;

D O I：

10.1586/17469899.3.1.97

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

The purine analogs, fludarabine and cladribine represent an important class of chemotherapy agents used to treat a broad spectrum of lymphoid malignancies. Their toxicity profiles include dose-limiting myelosuppression, immunosuppression, opportunistic infection and severe neurotoxicity. This review summarizes the neurotoxicity of high-and standard-dose fludarabine, focusing on the clinical and pathological manifestations in the eye. The mechanisms of ocular toxicity are probably multifactorial. With increasing clinical use, an awareness of the neurological and ocular vulnerability, particularly to fludarabine, is important owing to the potential for life-and sight-threatening consequences.

引用

页码：97 / 109

页数：13

共 59 条

[1]

Adkins JC, 1997, DRUGS, V53, P1005

[2] Infections in patients with chronic lymphocytic leukemia treated with fludarabine [J].

Anaissie, EJ ;

Kontoyiannis, DP ;

O'Brien, S ;

Kantarjian, H ;

Robertson, L ;

Lerner, S ;

Keating, MJ .

ANNALS OF INTERNAL MEDICINE, 1998, 129 (07) :559-566

[3] METABOLISM OF 9-BETA-D-ARABINOSYL-2-FLUOROADENINE-5'-PHOSPHATE BY MICE BEARING P388 LEUKEMIA [J].

AVRAMIS, VI ;

PLUNKETT, W .

CANCER DRUG DELIVERY, 1983, 1 (01) :1-10

[4] Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3) [J].

Badagnani, I ;

Chan, W ;

Castro, RA ;

Brett, CM ;

Huang, CC ;

Stryke, D ;

Kawamoto, M ;

Johns, SJ ;

Ferrin, TE ;

Carlson, EJ ;

Burchard, EG ;

Giacomini, KM .

PHARMACOGENOMICS JOURNAL, 2005, 5 (03) :157-165

[5]

BALDUCCI L, 1987, CANCER TREAT REP, V71, P543

[6] Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation [J].

Blau, I. W. ;

Schmidt-Hieber, Martin ;

Leschinger, N. ;

Goeldner, H. ;

Knauf, W. ;

Hopfenmueller, W. ;

Thiel, E. ;

Blau, O. .

ANNALS OF HEMATOLOGY, 2007, 86 (08) :583-589

[7] Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial [J].

Catovsky, D. ;

Richards, S. ;

Matutes, E. ;

Oscier, D. ;

Dyer, M. J. S. ;

FBezares, R. ;

Pettitt, A. R. ;

Hamblin, T. ;

Milligan, D. W. ;

Child, J. A. ;

Hamilton, M. S. ;

Dearden, C. E. ;

Smith, A. G. ;

Bosanquet, A. G. ;

Davis, Z. ;

Brito-Babapulle, V. ;

Else, M. ;

Wade, R. ;

Hillmen, P. .

LANCET, 2007, 370 (9583) :230-239

[8] Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL) [J].

Chanan-Khan, A ;

Miller, KC ;

Takeshita, K ;

Koryzna, A ;

Donohue, K ;

Bernstein, ZP ;

Mohr, A ;

Klippenstein, D ;

Wallace, P ;

Zeldis, JB ;

Berger, C ;

Czuczman, MS .

BLOOD, 2005, 106 (10) :3348-3352

[9] Sight-threatening varicella zoster virus infection after fludarabine treatment [J].

Chee, YL ;

Culligan, DJ ;

Olson, JA ;

Molyneaux, P ;

Kurtz, JB ;

Watson, HG .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (04) :874-875

[10] NEUROTOXICITY OF PURINE ANALOGS - A REVIEW [J].

CHESON, BD ;

VENA, DA ;

FOSS, FM ;

SORENSEN, JM .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) :2216-2228

← 1 2 3 4 5 6 →